KR100827502B1 - 이바브라딘 히드로클로라이드의 β-결정형, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 - Google Patents
이바브라딘 히드로클로라이드의 β-결정형, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 Download PDFInfo
- Publication number
- KR100827502B1 KR100827502B1 KR1020060018722A KR20060018722A KR100827502B1 KR 100827502 B1 KR100827502 B1 KR 100827502B1 KR 1020060018722 A KR1020060018722 A KR 1020060018722A KR 20060018722 A KR20060018722 A KR 20060018722A KR 100827502 B1 KR100827502 B1 KR 100827502B1
- Authority
- KR
- South Korea
- Prior art keywords
- hydrochloride
- expressed
- crystalline form
- line
- coefficient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
- D21H27/10—Packing paper
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
- B65D85/30—Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
- D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
- D21H21/16—Sizing or water-repelling agents
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H27/00—Special paper not otherwise provided for, e.g. made by multi-step processes
- D21H27/30—Multi-ply
- D21H27/40—Multi-ply at least one of the sheets being non-planar, e.g. crêped
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Mechanical Engineering (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
선 번호 | 각 2 θ(°) | 높이(계수) | 영역(계수 × °) | FWHM(°) | 결정면간 거리(Å) |
1 | 6.8 | 130 | 86 | 0.6691 | 13.019 |
2 | 9.2 | 6141 | 507 | 0.0836 | 9.613 |
3 | 9.7 | 882 | 58 | 0.0669 | 9.083 |
4 | 10.0 | 875 | 72 | 0.0836 | 8.837 |
5 | 11.9 | 190 | 19 | 0.1004 | 7.433 |
6 | 12.2 | 500 | 58 | 0.1171 | 7.236 |
7 | 13.2 | 224 | 30 | 0.1338 | 6.694 |
8 | 13.8 | 633 | 52 | 0.0836 | 6.419 |
9 | 14.3 | 466 | 54 | 0.1171 | 6.209 |
10 | 14.8 | 926 | 76 | 0.0836 | 5.977 |
11 | 15.0 | 716 | 94 | 0.1338 | 5.887 |
12 | 15.7 | 531 | 79 | 0.1506 | 5.636 |
13 | 16.1 | 121 | 16 | 0.1338 | 5.502 |
14 | 16.9 | 1354 | 223 | 0.1673 | 5.254 |
15 | 18.4 | 5672 | 562 | 0.1004 | 4.824 |
16 | 18.8 | 1328 | 131 | 0.1004 | 4.716 |
17 | 19.7 | 1617 | 347 | 0.2175 | 4.508 |
18 | 20.4 | 296 | 34 | 0.1171 | 4.341 |
19 | 20.7 | 767 | 51 | 0.0669 | 4.286 |
20 | 21.3 | 1419 | 211 | 0.1506 | 4.178 |
21 | 21.6 | 2458 | 243 | 0.1004 | 4.114 |
22 | 22.6 | 1737 | 258 | 0.1506 | 3.937 |
23 | 23.0 | 1467 | 73 | 0.0502 | 3.865 |
24 | 23.7 | 486 | 128 | 0.2676 | 3.751 |
25 | 23.9 | 504 | 50 | 0.1004 | 3.718 |
26 | 25.3 | 4606 | 304 | 0.0669 | 3.513 |
27 | 25.7 | 791 | 91 | 0.1171 | 3.464 |
28 | 26.2 | 458 | 91 | 0.2007 | 3.406 |
29 | 26.6 | 221 | 44 | 0.2007 | 3.352 |
30 | 27.4 | 706 | 151 | 0.2175 | 3.251 |
31 | 27.7 | 208 | 27 | 0.1338 | 3.215 |
32 | 28.1 | 483 | 40 | 0.0836 | 3.176 |
33 | 28.8 | 242 | 24 | 0.1004 | 3.096 |
34 | 29.3 | 450 | 74 | 0.1673 | 3.049 |
선 번호 | 각 2 θ(°) | 높이(계수) | 영역(계수 × °) | FWHM(°) | 결정면간 거리(Å) |
1 | 6.8 | 130 | 86 | 0.6691 | 13.019 |
2 | 9.2 | 6141 | 507 | 0.0836 | 9.613 |
3 | 9.7 | 882 | 58 | 0.0669 | 9.083 |
4 | 10.0 | 875 | 72 | 0.0836 | 8.837 |
5 | 11.9 | 190 | 19 | 0.1004 | 7.433 |
6 | 12.2 | 500 | 58 | 0.1171 | 7.236 |
7 | 13.2 | 224 | 30 | 0.1338 | 6.694 |
8 | 13.8 | 633 | 52 | 0.0836 | 6.419 |
9 | 14.3 | 466 | 54 | 0.1171 | 6.209 |
10 | 14.8 | 926 | 76 | 0.0836 | 5.977 |
11 | 15.0 | 716 | 94 | 0.1338 | 5.887 |
12 | 15.7 | 531 | 79 | 0.1506 | 5.636 |
13 | 16.1 | 121 | 16 | 0.1338 | 5.502 |
14 | 16.9 | 1354 | 223 | 0.1673 | 5.254 |
15 | 18.4 | 5672 | 562 | 0.1004 | 4.824 |
16 | 18.8 | 1328 | 131 | 0.1004 | 4.716 |
17 | 19.7 | 1617 | 347 | 0.2175 | 4.508 |
18 | 20.4 | 296 | 34 | 0.1171 | 4.341 |
19 | 20.7 | 767 | 51 | 0.0669 | 4.286 |
20 | 21.3 | 1419 | 211 | 0.1506 | 4.178 |
21 | 21.6 | 2458 | 243 | 0.1004 | 4.114 |
22 | 22.6 | 1737 | 258 | 0.1506 | 3.937 |
23 | 23.0 | 1467 | 73 | 0.0502 | 3.865 |
24 | 23.7 | 486 | 128 | 0.2676 | 3.751 |
25 | 23.9 | 504 | 50 | 0.1004 | 3.718 |
26 | 25.3 | 4606 | 304 | 0.0669 | 3.513 |
27 | 25.7 | 791 | 91 | 0.1171 | 3.464 |
28 | 26.2 | 458 | 91 | 0.2007 | 3.406 |
29 | 26.6 | 221 | 44 | 0.2007 | 3.352 |
30 | 27.4 | 706 | 151 | 0.2175 | 3.251 |
31 | 27.7 | 208 | 27 | 0.1338 | 3.215 |
32 | 28.1 | 483 | 40 | 0.0836 | 3.176 |
33 | 28.8 | 242 | 24 | 0.1004 | 3.096 |
34 | 29.3 | 450 | 74 | 0.1673 | 3.049 |
Claims (7)
- 패널리티컬 엑스퍼트 프로(PANalytical X'Pert Pro) 회절분석기와 엑스셀러레이터(X'Celerator) 검출기를 사용하여 측정되고, 선 위치(브래그 각(Bragg's angle) 2 θ, °로 표시됨), 선 높이(계수로 표시됨), 선 영역(계수 × °로 표시됨), 반높이에서의 선 폭("FWHM", °로 표시됨) 및 결정면간 거리 d(Å으로 표시됨)로 표현된 하기의 분말 X-선 회절(powder X-ray diffraction) 도표를 특징으로 하는, 하기 화학식(Ⅰ)의 β-결정형의 이바브라딘 히드로클로라이드:
선 번호 각 2 θ(°) 높이(계수) 영역(계수 × °) FWHM(°) 결정면간 거리(Å) 1 6.8 130 86 0.6691 13.019 2 9.2 6141 507 0.0836 9.613 3 9.7 882 58 0.0669 9.083 4 10.0 875 72 0.0836 8.837 5 11.9 190 19 0.1004 7.433 6 12.2 500 58 0.1171 7.236 7 13.2 224 30 0.1338 6.694 8 13.8 633 52 0.0836 6.419 9 14.3 466 54 0.1171 6.209 10 14.8 926 76 0.0836 5.977 11 15.0 716 94 0.1338 5.887 12 15.7 531 79 0.1506 5.636 13 16.1 121 16 0.1338 5.502 14 16.9 1354 223 0.1673 5.254 15 18.4 5672 562 0.1004 4.824 16 18.8 1328 131 0.1004 4.716 17 19.7 1617 347 0.2175 4.508 18 20.4 296 34 0.1171 4.341 19 20.7 767 51 0.0669 4.286 20 21.3 1419 211 0.1506 4.178 21 21.6 2458 243 0.1004 4.114 22 22.6 1737 258 0.1506 3.937 23 23.0 1467 73 0.0502 3.865 24 23.7 486 128 0.2676 3.751 25 23.9 504 50 0.1004 3.718 26 25.3 4606 304 0.0669 3.513 27 25.7 791 91 0.1171 3.464 28 26.2 458 91 0.2007 3.406 29 26.6 221 44 0.2007 3.352 30 27.4 706 151 0.2175 3.251 31 27.7 208 27 0.1338 3.215 32 28.1 483 40 0.0836 3.176 33 28.8 242 24 0.1004 3.096 34 29.3 450 74 0.1673 3.049 - 이바브라딘 히드로클로라이드 및 물의 혼합물, 또는 이바브라딘 히드로클로라이드, 이소프로판올 및 물의 혼합물을 용해가 완결될 때까지 가열한 후, 결정화가 완결될 때까지 점진적으로 냉각시키고, 형성된 결정을 수거함을 특징으로 하는, β-결정형의 이바브라딘 히드로클로라이드를 제조하는 방법.
- 제 2 항에 있어서, 이바브라딘 히드로클로라이드 용액이 냉각 단계 동안 시 딩(seeding)됨을 특징으로 하는 방법.
- 활성 성분으로서 제 1 항에 따른 β-결정형의 이바브라딘 히드로클로라이드와 하나 이상의 약제학적으로 허용되는 비활성의 무독성 담체를 포함하는 서맥제(bradycardics)로 사용되는 약제학적 조성물.
- 삭제
- 삭제
- 활성 성분으로서 제 1 항에 따른 β-결정형의 이바브라딘 히드로클로라이드와 하나 이상의 약제학적으로 허용되는 비활성의 무독성 담체를 포함하는 심근 허혈, 협심증, 심근경색증, 리듬 장애, 심실위 리듬 장애 또는 심부전을 치료 또는 예방하기 위한 약제학적 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501985A FR2882553B1 (fr) | 2005-02-28 | 2005-02-28 | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR05.01985 | 2005-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060095501A KR20060095501A (ko) | 2006-08-31 |
KR100827502B1 true KR100827502B1 (ko) | 2008-05-06 |
Family
ID=34954954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060018722A KR100827502B1 (ko) | 2005-02-28 | 2006-02-27 | 이바브라딘 히드로클로라이드의 β-결정형, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 |
Country Status (43)
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882555B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882556B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891826B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2891827B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2894825B1 (fr) * | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
EP2097383B1 (en) | 2006-11-30 | 2012-02-08 | Cadila Healthcare Limited | Process for preparation of ivabradine hydrochloride |
FR2911279B1 (fr) * | 2007-01-11 | 2009-03-06 | Servier Lab | Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale |
CN101353325B (zh) * | 2007-07-27 | 2011-11-09 | 上海优拓医药科技有限公司 | 稳定型盐酸伊伐布雷定结晶及其制备方法 |
US8212026B2 (en) | 2007-05-30 | 2012-07-03 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
FR2938194B1 (fr) * | 2008-11-07 | 2012-08-31 | Servier Lab | Utilisation de l'ivabradine comme agent de diagnostic dans la methode d'angiographie coronaire par tomodensitometrie multicoupe |
WO2010072409A1 (en) | 2008-12-22 | 2010-07-01 | Krka, D. D., Novo Mesto | Process for preparation of ivabradine |
CN101774969B (zh) | 2009-01-13 | 2012-07-04 | 江苏恒瑞医药股份有限公司 | 硫酸伊伐布雷定及其i型结晶的制备方法 |
EP2902384B1 (en) | 2010-02-12 | 2017-11-08 | KRKA, D.D., Novo Mesto | Form of ivabradine hydrochloride |
HUP1000245A2 (en) | 2010-05-07 | 2011-11-28 | Richter Gedeon Nyrt | Industrial process for the production ivabradin salts |
TWI499587B (zh) * | 2010-06-03 | 2015-09-11 | Jiangsu Hengrui Medicine Co | 硫酸伊伐佈雷定及其i型結晶的製備方法 |
US20130084335A1 (en) | 2010-06-14 | 2013-04-04 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition |
WO2012025940A1 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Polymorphic form of ivabradine hydrochloride and process for preparation thereof |
CN102304088B (zh) * | 2011-07-07 | 2013-06-19 | 石药集团欧意药业有限公司 | 一种伊伐布雷定化合物、制备方法及其药物组合物 |
EP2726462B1 (en) | 2011-08-02 | 2017-03-22 | Sandoz AG | Acetone solvate of ivabradine hydrochloride |
WO2013064427A1 (en) | 2011-11-04 | 2013-05-10 | Synthon Bv | A process for making crystalline delta-form of ivabradine hydrochloride |
EP2589594A1 (en) | 2011-11-04 | 2013-05-08 | Urquima S.A. | Ivabradine hydrochloride Form IV |
US9120755B2 (en) | 2011-11-14 | 2015-09-01 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
US9409913B2 (en) * | 2012-11-21 | 2016-08-09 | Enaltec Labs Private Limited | Polymorphic forms of alcaftadine |
WO2014114341A1 (en) | 2013-01-24 | 2014-07-31 | Synthon Bv | Process for making ivabradine |
EP2781509B2 (en) | 2013-03-19 | 2023-06-14 | Chemo Research, S.L. | New polymorph of ivabradine hydrochloride and method for its preparation |
CZ305096B6 (cs) | 2013-10-02 | 2015-04-29 | Zentiva, K.S. | Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice |
ES2672472T3 (es) | 2013-12-12 | 2018-06-14 | Synthon Bv | Composición farmacéutica que comprende ivabradina amorfa |
EP2774606B1 (en) | 2014-02-14 | 2019-01-30 | Synthon B.V. | Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV |
CZ305436B6 (cs) | 2014-07-10 | 2015-09-16 | Zentiva, K.S. | Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice |
WO2016102423A1 (en) | 2014-12-22 | 2016-06-30 | Ratiopharm Gmbh | Composition comprising ivabradine in a dissolved form |
GR1008821B (el) | 2015-06-11 | 2016-08-01 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου |
CN107056706B (zh) * | 2015-12-21 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种用于制备盐酸伊伐布雷定α晶型的方法 |
WO2017173458A1 (en) * | 2016-04-01 | 2017-10-05 | Swiderski Cyprianna | Compositions and methods targeting hcn channels for breathing therapeutics |
TR201703066A2 (tr) | 2017-02-28 | 2018-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari |
EP3366282A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
US20230181472A1 (en) | 2018-10-30 | 2023-06-15 | Amgen Inc. | Process of making ivabradine hydrochloride drug product |
CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
IT202000025312A1 (it) | 2020-10-26 | 2022-04-26 | Cambrex Profarmaco Milano S R L | Processi per la preparazione di polimorfi di ivabradina hcl |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5296481A (en) | 1990-08-29 | 1994-03-22 | Humanetics Corporation | Treatment process for promoting weight loss employing a substituted Δ5 |
KR20040075366A (ko) * | 2002-01-23 | 2004-08-27 | 르 라보레또레 쎄르비에르 | 이바브라딘을 포함하는 구강내분산성 약제 조성물 |
KR100542472B1 (ko) | 2000-12-26 | 2006-01-11 | 르 라보레또레 쎄르비에르 | 이바브라딘의 조절 방출을 위한 열성형가능한 고체 약제조성물 |
KR20060042116A (ko) * | 2004-04-13 | 2006-05-12 | 르 라보레또레 쎄르비에르 | 이바브라딘 및 이와 약제학적으로 허용되는 산과의 부가염을 합성하는 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4490369A (en) * | 1981-05-19 | 1984-12-25 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Benzazepine derivatives, their pharmaceutical compositions and method of use |
DE3119874A1 (de) * | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
FR2882554B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882553B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882555B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2882556B1 (fr) * | 2005-02-28 | 2007-05-04 | Servier Lab | Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891827B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2891826B1 (fr) * | 2005-10-11 | 2007-12-28 | Servier Lab | Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2005
- 2005-02-28 FR FR0501985A patent/FR2882553B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-13 MA MA28792A patent/MA28131A1/fr unknown
- 2006-02-14 PE PE2006000169A patent/PE20061009A1/es active IP Right Grant
- 2006-02-14 JO JO200650A patent/JO2548B1/en active
- 2006-02-15 EC EC2006006375A patent/ECSP066375A/es unknown
- 2006-02-15 EC EC2006006373A patent/ECSP066373A/es unknown
- 2006-02-21 CR CR8248A patent/CR8248A/es unknown
- 2006-02-21 SG SG200601133A patent/SG125228A1/en unknown
- 2006-02-22 AP AP2006003519A patent/AP1907A/xx active
- 2006-02-22 GT GT200600084A patent/GT200600084A/es unknown
- 2006-02-22 TW TW095105987A patent/TWI314144B/zh active
- 2006-02-22 CU CU20060039A patent/CU23614B7/es active IP Right Grant
- 2006-02-22 US US11/358,954 patent/US7361649B2/en active Active
- 2006-02-23 BR BRPI0600623-0A patent/BRPI0600623A/pt not_active Application Discontinuation
- 2006-02-24 UY UY29405A patent/UY29405A1/es not_active Application Discontinuation
- 2006-02-24 CA CA2537414A patent/CA2537414C/fr active Active
- 2006-02-27 KR KR1020060018722A patent/KR100827502B1/ko active IP Right Grant
- 2006-02-27 MY MYPI20060819A patent/MY158128A/en unknown
- 2006-02-27 NZ NZ545576A patent/NZ545576A/en unknown
- 2006-02-27 UA UAA200602129A patent/UA80904C2/uk unknown
- 2006-02-27 EA EA200600322A patent/EA008464B1/ru unknown
- 2006-02-27 IL IL173957A patent/IL173957A0/en active IP Right Grant
- 2006-02-27 GE GEAP20069263A patent/GEP20084465B/en unknown
- 2006-02-27 NO NO20060946A patent/NO338370B1/no unknown
- 2006-02-27 SA SA06270038A patent/SA06270038B1/ar unknown
- 2006-02-28 CN CN2006100580765A patent/CN1827600B/zh active Active
- 2006-02-28 RS RSP-2008/0551A patent/RS50661B/sr unknown
- 2006-02-28 AT AT06290326T patent/ATE407926T1/de active
- 2006-02-28 ME MEP-2008-551A patent/ME01408B/me unknown
- 2006-02-28 WO PCT/FR2006/000444 patent/WO2006092493A1/fr not_active Application Discontinuation
- 2006-02-28 JP JP2006051647A patent/JP4625776B2/ja active Active
- 2006-02-28 PT PT06290326T patent/PT1695965E/pt unknown
- 2006-02-28 DK DK06290326T patent/DK1695965T3/da active
- 2006-02-28 SI SI200630111T patent/SI1695965T1/sl unknown
- 2006-02-28 DE DE602006002624T patent/DE602006002624D1/de active Active
- 2006-02-28 PL PL06290326T patent/PL1695965T3/pl unknown
- 2006-02-28 EP EP06290326A patent/EP1695965B9/fr active Active
- 2006-02-28 CO CO06019926A patent/CO5770096A1/es not_active Application Discontinuation
- 2006-02-28 AR ARP060100728A patent/AR053147A1/es not_active Application Discontinuation
- 2006-02-28 ES ES06290326T patent/ES2313581T3/es active Active
- 2006-02-28 ZA ZA200601762A patent/ZA200601762B/xx unknown
-
2007
- 2007-02-01 HK HK07101190.9A patent/HK1096387A1/xx unknown
-
2008
- 2008-02-26 US US12/072,461 patent/US20080161285A1/en not_active Abandoned
- 2008-09-30 CY CY20081101080T patent/CY1109072T1/el unknown
- 2008-11-27 HR HR20080520T patent/HRP20080520T3/xx unknown
-
2009
- 2009-10-21 US US12/589,283 patent/US7879842B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5296481A (en) | 1990-08-29 | 1994-03-22 | Humanetics Corporation | Treatment process for promoting weight loss employing a substituted Δ5 |
KR100542472B1 (ko) | 2000-12-26 | 2006-01-11 | 르 라보레또레 쎄르비에르 | 이바브라딘의 조절 방출을 위한 열성형가능한 고체 약제조성물 |
KR20040075366A (ko) * | 2002-01-23 | 2004-08-27 | 르 라보레또레 쎄르비에르 | 이바브라딘을 포함하는 구강내분산성 약제 조성물 |
KR20060042116A (ko) * | 2004-04-13 | 2006-05-12 | 르 라보레또레 쎄르비에르 | 이바브라딘 및 이와 약제학적으로 허용되는 산과의 부가염을 합성하는 방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100827502B1 (ko) | 이바브라딘 히드로클로라이드의 β-결정형, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 | |
KR100835446B1 (ko) | 이바브라딘 히드로클로라이드의 βd-결정질 형태, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 | |
KR100835447B1 (ko) | 이바브라딘 히드로클로라이드의 γ-결정질 형태, 이의 제조방법 및 이를 함유하는 약제학적 조성물 | |
KR100827503B1 (ko) | 이바브라딘 히드로클로라이드의 γd-결정형, 이의 제조 방법 및 이를 함유하는 약제학적 조성물 | |
US7384932B2 (en) | δd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
US7358240B2 (en) | δ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
MXPA06002274A (en) | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130226 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140127 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160205 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170206 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180312 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190307 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20200224 Year of fee payment: 13 |